NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Startek, Inc. (NASDAQ:SRT) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 5:00 PM Eastern ...
HOUSTON, March 05, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it.
Bellicum Pharmaceuticals, Inc. (BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Compensation Committee of the Board of Directors has approved an inducement award consisting of a stock option to purchase up to 156,000 shares of the Company’s common stock to David E. Strauss. The stock option was granted on January 31, 2020 with an exercise price equal to the closing price of the Company’s common stock on such date. One-fourth of the shares subject to the stock option will vest on the one-year anniversary of Mr. Strauss’ start date and the remainder of the shares will vest in a series of 36 successive equal monthly installments thereafter.
Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
HOUSTON, May 27, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology.
Two publicly traded, clinical-stage pharmaceutical companies in Houston worked to better their financial runways Feb. 6 — one through a share purchase agreement, the other through a reverse stock split. Houston-based Moleculin Biotech Inc. (Nasdaq: MBRX), a clinical-stage pharmaceutical company targeting highly resistant tumors, announced a registered direct offering with institutional investors in a Feb. 6 news release. The agreement allows for Moleculin's investors to purchase an aggregate of up to 7.5 million shares and warrants to purchase 5.625 million shares of common stock at a combined public offering price of 80 cents per share.
NEW YORK, NY / ACCESSWIRE / January 31, 2020 / Levi & Korsinsky announces it has commenced an investigation of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) concerning possible breaches of fiduciary duty. ...
Rick Fair has been the CEO of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) since 2017. First, this article will...
The Compensation Committee of the Board of Directors approved the grants with an effective date of April 30, 2020. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $5.00 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company.
M.D. Anderson has halted research and development activity on the Houston pharmaceutical firm's product candidates in response to the COVID-19 pandemic.
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...
Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement.
The effective time of the reverse stock split will be 5 p.m. ET on February 5, 2020. The Company’s common stock will begin trading on a split-adjusted basis commencing upon market open on February 6, 2020. As previously disclosed, at a special meeting of stockholders held on January 15, 2020, the Company’s stockholders voted to approve a proposal authorizing the Board of Directors of the Company to amend the Company’s certificate of incorporation to effect a reverse stock split and a corresponding reduction in the authorized shares of the Company’s common stock.
Q4 2019 Bellicum Pharmaceuticals Inc Earnings Call
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 ...
HOUSTON, May 27, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that.
Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Purchase price of $15 million from sale of manufacturing, office and laboratory facility Current and future GoCAR™ product candidates to be manufactured by MD Anderson.